Sci Rep:Norrin保护视神经轴突免受青光眼病变引起的退化影响!

2017-11-15 cuiguizhong MedSci原创

德国雷根斯堡雷根斯堡大学人体解剖与胚胎学研究所的Leopold SA近日在Sci Rep杂志上发表了他们近期的一项工作。Norrin是激活Wnt /β-catenin 途径的分泌信号分子。由于Norrin具有保护视网膜神经元免受急性损伤的作用,作者对Norrin是否减少了青光眼小鼠模型中视网膜神经节细胞(RGC)及其轴突的慢性损伤进行了研究。

德国雷根斯堡雷根斯堡大学人体解剖与胚胎学研究所的Leopold SA近日在Sci Rep杂志上发表了他们近期的一项工作。Norrin是激活Wnt /β-catenin 途径的分泌信号分子。由于Norrin具有保护视网膜神经元免受急性损伤的作用,作者对Norrin是否减少了青光眼小鼠模型中视网膜神经节细胞(RGC)及其轴突的慢性损伤进行了研究。

构建视网膜中过表达Norrin的转基因小鼠(Pax6-Norrin),并与具有遗传性青光眼和视神经轴突变性的DBA / 2J小鼠杂交。

研究发现,一岁的DBA / 2J / Pax6-Norrin小鼠比其它DBA / 2J同窝出生的小鼠,存活的视神经轴突更多。这种保护作用可能与胰岛素样生长因子(IGF)-1 mRNA的增加和DBA / 2J / Pax6-Norrin小鼠中Akt磷酸化程度增强有关。在第一年下半年,两只小鼠的眼压均发现升高,并且明显改变了房室角度、睫状体和虹膜结构。DBA / 2J / Pax6-Norrin小鼠的房室角度的衰退是轻微衰退的。同时,小梁网中β-catenin 也出现增加现象。

他们得出结论,高水平的Norrin和随后视网膜神经节细胞(RGC)产生的持续激活的Wnt /β-catenin信号传导途径,是通过IGF-1来防止青光眼轴突损伤,进而导致PI3K-Akt信号途径的活性增加。他们的研究结果具有重要的应用价值,文章中指出的保护性信号调控网络可以用于防止青光眼视神经轴突的变性。

原文出处:

Leopold, S.A., et al. Norrin protects optic nerve axons from degeneration in a mouse model of glaucoma. Sci Rep, 2017. 7(1): p. 14274.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1666956, encodeId=523d166695614, content=<a href='/topic/show?id=5fda90e061e' target=_blank style='color:#2F92EE;'>#视神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90706, encryptionId=5fda90e061e, topicName=视神经)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14db26078051, createdName=gj0740, createdTime=Sun Jun 17 10:14:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540503, encodeId=1748154050393, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Fri Nov 17 13:14:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590686, encodeId=61f51590686bd, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13478, encryptionId=e31d134e83e, topicName=ORR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b17846501, createdName=psybestwish, createdTime=Fri Nov 17 13:14:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261827, encodeId=e6b326182ed6, content=不错的文章值得推荐., beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Thu Nov 16 23:08:28 CST 2017, time=2017-11-16, status=1, ipAttribution=)]
    2018-06-17 gj0740
  2. [GetPortalCommentsPageByObjectIdResponse(id=1666956, encodeId=523d166695614, content=<a href='/topic/show?id=5fda90e061e' target=_blank style='color:#2F92EE;'>#视神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90706, encryptionId=5fda90e061e, topicName=视神经)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14db26078051, createdName=gj0740, createdTime=Sun Jun 17 10:14:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540503, encodeId=1748154050393, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Fri Nov 17 13:14:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590686, encodeId=61f51590686bd, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13478, encryptionId=e31d134e83e, topicName=ORR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b17846501, createdName=psybestwish, createdTime=Fri Nov 17 13:14:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261827, encodeId=e6b326182ed6, content=不错的文章值得推荐., beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Thu Nov 16 23:08:28 CST 2017, time=2017-11-16, status=1, ipAttribution=)]
    2017-11-17 pps20023
  3. [GetPortalCommentsPageByObjectIdResponse(id=1666956, encodeId=523d166695614, content=<a href='/topic/show?id=5fda90e061e' target=_blank style='color:#2F92EE;'>#视神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90706, encryptionId=5fda90e061e, topicName=视神经)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14db26078051, createdName=gj0740, createdTime=Sun Jun 17 10:14:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540503, encodeId=1748154050393, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Fri Nov 17 13:14:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590686, encodeId=61f51590686bd, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13478, encryptionId=e31d134e83e, topicName=ORR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b17846501, createdName=psybestwish, createdTime=Fri Nov 17 13:14:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261827, encodeId=e6b326182ed6, content=不错的文章值得推荐., beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Thu Nov 16 23:08:28 CST 2017, time=2017-11-16, status=1, ipAttribution=)]
    2017-11-17 psybestwish
  4. [GetPortalCommentsPageByObjectIdResponse(id=1666956, encodeId=523d166695614, content=<a href='/topic/show?id=5fda90e061e' target=_blank style='color:#2F92EE;'>#视神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90706, encryptionId=5fda90e061e, topicName=视神经)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14db26078051, createdName=gj0740, createdTime=Sun Jun 17 10:14:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540503, encodeId=1748154050393, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Fri Nov 17 13:14:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590686, encodeId=61f51590686bd, content=<a href='/topic/show?id=e31d134e83e' target=_blank style='color:#2F92EE;'>#ORR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13478, encryptionId=e31d134e83e, topicName=ORR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b17846501, createdName=psybestwish, createdTime=Fri Nov 17 13:14:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261827, encodeId=e6b326182ed6, content=不错的文章值得推荐., beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Thu Nov 16 23:08:28 CST 2017, time=2017-11-16, status=1, ipAttribution=)]
    2017-11-16 1e1b8538m79(暂无匿称)

    不错的文章值得推荐.

    0